The Conversation (0)
Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results
May. 08, 2018 09:46AM PST
Pharmaceutical InvestingAquinox Pharmaceuticals (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the first quarter ending March 31, 2018. As quoted in the press release: “The first quarter was important as we surpassed recruitment targets and completed …
Aquinox Pharmaceuticals (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the first quarter ending March 31, 2018.
As quoted in the press release:
“The first quarter was important as we surpassed recruitment targets and completed enrollment of the LEADERSHIP 301 Phase 3 clinical trial in subjects with interstitial cystitis/bladder pain syndrome (IC/BPS),” said David Main, President & CEO of Aquinox. “IC/BPS remains an area of high unmet medical need with few effective treatments available. We remain on track for sharing the topline results of this trial in Q3.”
